GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

AS Levey, LA Inker, K Matsushita, T Greene… - American Journal of …, 2014 - Elsevier
The US Food and Drug Administration currently accepts halving of glomerular filtration rate
(GFR), assessed as doubling of serum creatinine level, as a surrogate end point for the …

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

HJL Heerspink, T Greene, H Tighiouart… - The lancet Diabetes & …, 2019 - thelancet.com
Background Change in albuminuria has strong biological plausibility as a surrogate
endpoint for progression of chronic kidney disease, but empirical evidence to support its …

GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials

LA Inker, HJL Heerspink, H Mondal, CH Schmid… - American journal of …, 2014 - Elsevier
Background There is increased interest in using alternative end points for trials of kidney
disease progression. The currently established end points of end-stage renal disease and …

Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis

LA Inker, AS Levey, K Pandya, N Stoycheff… - American journal of …, 2014 - Elsevier
Background It is controversial whether proteinuria is a valid surrogate end point for
randomized trials in chronic kidney disease. Study Design Meta-analysis of individual …

GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials

HJL Heerspink, H Tighiouart, Y Sang, S Ballew… - American journal of …, 2014 - Elsevier
Background The currently established end points for clinical trials of progression of chronic
kidney disease (CKD) are end-stage renal disease and doubling of serum creatinine level …

Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress

L Raij, R Tian, JS Wong, JC He… - American Journal of …, 2016 - journals.physiology.org
Podocytes are the key target for injury in proteinuric glomerular diseases that result in
podocyte loss, progressive focal segmental glomerular sclerosis (FSGS), and renal failure …

Utility and validity of estimated GFR–based surrogate time-to-event end points in CKD: a simulation study

T Greene, CC Teng, LA Inker, A Redd, J Ying… - American journal of …, 2014 - Elsevier
Background There is interest in surrogate end points for clinical trials of chronic kidney
disease progression because currently established end points—end-stage renal disease …

[HTML][HTML] The IgA1 immune complex–mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA …

H Tamouza, JM Chemouny, LR Kafkova, L Berthelot… - Kidney international, 2012 - Elsevier
IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, has
significant morbidity and mortality as 20–40% of patients progress to end-stage renal …

Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 …

G Savarese, A Dei Cas, G Rosano, C D'Amore… - International journal of …, 2014 - Elsevier
Background The association between renal dysfunction and risk of cardiovascular (CV)
events and mortality has been reported in several studies. However, it is unclear whether …

[HTML][HTML] A systematic review comparing the evidence for kidney function outcomes between oral antidiabetic drugs for type 2 diabetes

SV Wilkinson, LA Tomlinson, M Iwagami… - Wellcome open …, 2018 - ncbi.nlm.nih.gov
Background: The development of kidney disease is a serious complication among people
with type 2 diabetes mellitus, associated with substantially increased morbidity and mortality …